AKARI Therapeutics Company
Akari is developing inhibitors of acute and chronic inflammation, specifically the complement and leukotriene systems, to treat rare and orphan diseases with unmet need.
Investment Stage:
N/A
Funding Status:
IPO
Headquarters:
United States
Industry:
Stem Cell Exhaustion
Number Of Exists:
N/A
Investor Type:
N/A
Technology:
Scientifically-Validated Lifestyle Recommendation
Employee Number:
11-50
Founded Date:
2005